EASYII - E-tegra Stent Graft System - Imaging Cohort

Inclusion Criteria:

• Age ≥ 65

• Patient must have an

• infrarenal aortic aneurysm with diameter ≥ 50 mm in females and ≥ 55 mm inmales, or

• infrarenal aortic aneurysm with 40-50 mm that has increased in size by ≥ 1 cmper year

• Patient is elegible for treatment inside the instructions for use of the E-tegraStent Graft System

• Patient is able and willing to undergo follow-up imaging and examinations prior todischarge from the hospital, at 30 days and 6 months, 12 months, and annuallythereafter until 5 years follow-up

• Patient understands and has signed the Informed Consent Form prior to intervention

• Patient has a life expectancy of at least 5 years

Exclusion Criteria:

• Patient with severe calcification or thrombi in the proximal sealing zone

• Patient with infectious aneurysm

• Patient with inflammatory aneurysm

• Patient with pseudoaneurysm

• Patient with symptomatic aneurysm

• Patient with ruptured or traumatic aneurysm

• Patient with suprarenal, juxtarenal, or pararenal aneurysm

• Patient with aortic dissection

• Patient with a reversed conical neck that is defined as a > 3 mm distal increaseover a 15 mm length

• Patient in which the E-tegra Stent Graft System is used in combination with proximalor distal extenders of another company.

• Patient who is planned to be treated with an adjunctive aortic bare metal stent or afenestrated stent graft

• Patient who is planned to be treated with a chimney / chimneys in the renal orvisceral vessels

• Patient who is planned to be treated with an iliac branch device or parallel graftsin the iliac vessels

• Patient with genetic connective tissue disease (e.g. Marfan syndrome orEhlers-Danlos syndrome)

• Patient with eGFR < 45 ml/min/1.73 m2 before the intervention Patient had or plannedto have a major surgical or interventional procedure within 30 days before or 30days after the planned implantation of the E-tegra Stent Graft System

• Patient with other medical condition that may cause the patient to be non-compliantwith the protocol, confound the results, or is associated with a limited lifeexpectancy of less than five years (i.e. heart failure, active malignancy (progressive, stable or partial remission))

• Patient who has been enrolled in another active clinical trial that does not allowinclusion in this trial